• United Therapeutics Chairperson and CEO Martine A. Rothblatt sold 9,500 common shares on October 16, 2026.
• Rothblatt also exercised stock options for 9,500 common shares at $117.76 per share on the same date.
• The transactions left 324,443 common shares held indirectly through trusts involved in the trades; direct holdings totaled 40,513 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000166), on October 19, 2026, and is solely responsible for the information contained therein.